Profile

Robert Matusik is professor of Urologic Surgery, Cancer Biology and Cell & Developmental Biology at Vanderbilt University School of Medicine and director of Urologic Research in the department of Urologic Surgery.  He earned his PhD in biochemistry at the University of Rochester in New York in 1976 and completed a post-doctoral fellowship in cell biology at the Baylor College of Medicine in 1979.  Matusik joined the faculty of the University of Manitoba (Canada) Department of Physiology in 1979 and grew through the ranks to the position of full professor by the time he left in 1996 to join Vanderbilt?s faculty.  He also served as a visit scientist for the British Columbia Cancer Agency, based in Vancouver, from 1992-1993.  Matusik holds numerous research grants from the National Institutes of Health and U.S. Department of Defense to support his research into the genetic, molecular and hormonal factors that contribute to the development and progression of prostate cancer.  He also serves as a co-investigator in a Department of Defense grant to support development of a prostate cancer program at Meharry Medical College, a historically black institution in Nashville and a collaborator with Vanderbilt through the Meharry-Vanderbilt Alliance.   A former Damon Runyon-Walter Winchell fellow, Matusik has served on numerous study sections, site visit teams and review committees for the National Institutes of Health, the Department of Defense and the Department of Veterans Affairs.  He also served on the editorial board of the journal Molecular Endocrinology.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Lu W, Liu S, Li B, Xie Y, Izban MG, Ballard BR, Sathyanarayana SA, Adunyah SE, Matusik RJ, Chen Z (2017) Oncogene 36(10): 1364-1373
    › Primary publication · 27869166 (PubMed)
  2. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R (2016) Oncotarget 7(38): 61955-61969
    › Primary publication · 27542219 (PubMed) · PMC5308703 (PubMed Central)
  3. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76(11): 1004-18
    › Primary publication · 27197599 (PubMed) · PMC4912960 (PubMed Central)
  4. NF-κB and androgen receptor variant expression correlate with human BPH progression. Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76(5): 491-511
    › Primary publication · 26709083 (PubMed) · PMC4763342 (PubMed Central)
  5. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ (2016) Endocrinology 157(3): 1094-109
    › Primary publication · 26677878 (PubMed) · PMC4769366 (PubMed Central)
  6. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ (2015) Am J Pathol 185(5): 1385-95
    › Primary publication · 25907831 (PubMed) · PMC4419202 (PubMed Central)
  7. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, Ballard BR, Nakayama KI, Matusik RJ, Chen Z (2015) Oncotarget 6(2): 771-88
    › Primary publication · 25596733 (PubMed) · PMC4359254 (PubMed Central)
  8. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2015) Oncogene 34(28): 3700-10
    › Primary publication · 25220414 (PubMed) · PMC4362792 (PubMed Central)
  9. Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia. Valkenburg KC, Yu X, De Marzo AM, Spiering TJ, Matusik RJ, Williams BO (2014) Prostate 74(15): 1506-20
    › Primary publication · 25175604 (PubMed) · PMC4175140 (PubMed Central)
  10. SOX2 expression in the developing, adult, as well as, diseased prostate. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ (2014) Prostate Cancer Prostatic Dis 17(4): 301-9
    › Primary publication · 25091041 (PubMed) · PMC4227931 (PubMed Central)
  11. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z (2014) Mol Oncol 8(7): 1355-64
    › Primary publication · 24910389 (PubMed) · PMC4198473 (PubMed Central)
  12. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ (2014) Lab Invest 94(7): 726-39
    › Primary publication · 24840332 (PubMed) · PMC4451837 (PubMed Central)
  13. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ (2014) Mol Endocrinol 28(6): 949-64
    › Primary publication · 24801505 (PubMed) · PMC4042066 (PubMed Central)
  14. NF-κB gene signature predicts prostate cancer progression. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ (2014) Cancer Res 74(10): 2763-72
    › Primary publication · 24686169 (PubMed) · PMC4024337 (PubMed Central)
  15. Mouse models of prostate cancer: picking the best model for the question. Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ (2014) Cancer Metastasis Rev 33(2-3): 377-97
    › Primary publication · 24452759 (PubMed) · PMC4108581 (PubMed Central)
  16. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. Li B, Lu W, Yang Q, Yu X, Matusik RJ, Chen Z (2014) Prostate 74(4): 421-32
    › Primary publication · 24347472 (PubMed) · PMC4062570 (PubMed Central)
  17. ARF represses androgen receptor transactivation in prostate cancer. Lu W, Xie Y, Ma Y, Matusik RJ, Chen Z (2013) Mol Endocrinol 27(4): 635-48
    › Primary publication · 23449888 (PubMed) · PMC3607697 (PubMed Central)
  18. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Gupta A, Yu X, Case T, Paul M, Shen MM, Kaestner KH, Matusik RJ (2013) Prostate 73(6): 582-9
    › Primary publication · 23060003 (PubMed) · PMC3714015 (PubMed Central)
  19. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ (2012) PLoS One 7(5): e36669
    › Primary publication · 22590586 (PubMed) · PMC3349679 (PubMed Central)
  20. Gender specific differences in bladder cancer. DeGraff DJ, Matusik RJ (2012) J Urol 188(1): 10-1
    › Primary publication · 22583637 (PubMed)
  21. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM (2013) Urol Oncol 31(6): 802-11
    › Primary publication · 21924649 (PubMed) · PMC4886548 (PubMed Central)
  22. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ (2011) Oncogene 30(16): 1868-79
    › Primary publication · 21151173 (PubMed) · PMC3081383 (PubMed Central)
  23. Human homolog of Drosophila Hairy and enhancer of split 1, Hes1, negatively regulates δ-catenin (CTNND2) expression in cooperation with E2F1 in prostate cancer. Lu JP, Zhang J, Kim K, Case TC, Matusik RJ, Chen YH, Wolfe M, Nopparat J, Lu Q (2010) Mol Cancer : 304
    › Primary publication · 21106062 (PubMed) · PMC3009707 (PubMed Central)
  24. Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression. Zhang J, Gao N, DeGraff DJ, Yu X, Sun Q, Case TC, Kasper S, Matusik RJ (2010) Prostate 70(9): 934-51
    › Primary publication · 20209642 (PubMed) · PMC3712623 (PubMed Central)
  25. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Sun Q, Yu X, Degraff DJ, Matusik RJ (2009) Mol Endocrinol 23(12): 2038-47
    › Primary publication · 19846536 (PubMed) · PMC2796152 (PubMed Central)
  26. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW (2010) Cell Death Differ 17(3): 469-81
    › Primary publication · 19834493 (PubMed) · PMC2821953 (PubMed Central)
  27. Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer. Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, Tsuchiya KD (2009) Mol Cytogenet : 18
    › Primary publication · 19781100 (PubMed) · PMC2761934 (PubMed Central)
  28. Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. Anumanthan G, Tanaka ST, Adams CM, Thomas JC, Wills ML, Adams MC, Hayward SW, Matusik RJ, Bhowmick NA, Brock JW, Pope JC (2009) J Urol 182(4 Suppl): 1775-80
    › Primary publication · 19692014 (PubMed) · PMC4797651 (PubMed Central)
  29. Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Li X, Wang Y, Sharif-Afshar AR, Uwamariya C, Yi A, Ishii K, Hayward SW, Matusik RJ, Bhowmick NA (2009) Differentiation 77(1): 95-102
    › Primary publication · 19281768 (PubMed) · PMC2733217 (PubMed Central)
  30. Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ (2009) Prostate 69(3): 249-62
    › Primary publication · 18991257 (PubMed) · PMC4437562 (PubMed Central)
  31. Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC, Brock JW, Hayward SW, Matusik RJ, Pope JC (2008) J Urol 180(4 Suppl): 1784-9
    › Primary publication · 18721943 (PubMed)
  32. Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. Anumanthan G, Makari JH, Honea L, Thomas JC, Wills ML, Bhowmick NA, Adams MC, Hayward SW, Matusik RJ, Brock JW, Pope JC (2008) J Urol 180(4 Suppl): 1778-83
    › Primary publication · 18721942 (PubMed) · PMC4802964 (PubMed Central)
  33. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ (2008) Cancer Res 68(16): 6762-9
    › Primary publication · 18701501 (PubMed) · PMC2840631 (PubMed Central)
  34. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA (2008) Cancer Res 68(12): 4709-18
    › Primary publication · 18559517 (PubMed) · PMC2811537 (PubMed Central)
  35. Down-regulation of p57Kip2 induces prostate cancer in the mouse. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ (2008) Cancer Res 68(10): 3601-8
    › Primary publication · 18483241 (PubMed)
  36. Prostate epithelial cell fate. Matusik RJ, Jin RJ, Sun Q, Wang Y, Yu X, Gupta A, Nandana S, Case TC, Paul M, Mirosevich J, Oottamasathien S, Thomas J (2008) Differentiation 76(6): 682-98
    › Primary publication · 18462434 (PubMed)
  37. Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Martinez-Ferrer M, Iturregui JM, Uwamariya C, Starkman J, Sharif-Afshar AR, Suzuki K, Visedsindh W, Matusik RJ, Dmochowski RR, Bhowmick NA (2008) Am J Pathol 172(1): 59-67
    › Primary publication · 18079438 (PubMed) · PMC2189612 (PubMed Central)
  38. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M, Wills ML, Matusik RJ (2008) Prostate 68(1): 50-60
    › Primary publication · 18004726 (PubMed)
  39. Epididymis-specific lipocalin promoters. Suzuki K, Yu X, Chaurand P, Araki Y, Lareyre JJ, Caprioli RM, Orgebin-Crist MC, Matusik RJ (2007) Asian J Androl 9(4): 515-21
    › Primary publication · 17589789 (PubMed)
  40. Directed differentiation of embryonic stem cells into bladder tissue. Oottamasathien S, Wang Y, Williams K, Franco OE, Wills ML, Thomas JC, Saba K, Sharif-Afshar AR, Makari JH, Bhowmick NA, DeMarco RT, Hipkens S, Magnuson M, Brock JW, Hayward SW, Pope JC, Matusik RJ (2007) Dev Biol 304(2): 556-66
    › Primary publication · 17289017 (PubMed) · PMC1994155 (PubMed Central)
  41. Androgen-dependent prostate epithelial cell selection by targeting ARR(2)PBneo to the LPB-Tag model of prostate cancer. Wang Y, Kasper S, Yuan J, Jin RJ, Zhang J, Ishii K, Wills ML, Hayward SW, Matusik RJ (2006) Lab Invest 86(10): 1074-88
    › Primary publication · 16894353 (PubMed)
  42. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist MC, Matusik RJ (2005) Ann N Y Acad Sci : 77-93
    › Primary publication · 16467259 (PubMed)
  43. Epididymis-specific promoter-driven gene targeting: a transcription factor which regulates epididymis-specific gene expression. Suzuki K, Yu X, Chaurand P, Araki Y, Lareyre JJ, Caprioli RM, Matusik RJ, Orgebin-Crist MC (2006) Mol Cell Endocrinol 250(1-2): 184-9
    › Primary publication · 16414179 (PubMed)
  44. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, Tsukamoto T (2006) Prostate 66(5): 536-45
    › Primary publication · 16372327 (PubMed)
  45. Molecular alterations in primary prostate cancer after androgen ablation therapy. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF (2005) Clin Cancer Res 11(19 Pt 1): 6823-34
    › Primary publication · 16203770 (PubMed) · PMC1432092 (PubMed Central)
  46. Expression and role of Foxa proteins in prostate cancer. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ (2006) Prostate 66(10): 1013-28
    › Primary publication · 16001449 (PubMed)
  47. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ (2005) Development 132(15): 3431-43
    › Primary publication · 15987773 (PubMed)
  48. Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Ishii K, Shappell SB, Matusik RJ, Hayward SW (2005) Lab Invest 85(9): 1086-103
    › Primary publication · 15980886 (PubMed)